SAHPRA’s position on GLP1 and GIP-GLP1 products that are compounded, substandard and falsified
- November 8, 2024
- Health
- 0 Comments
Pretoria, 08 November 2024 –The South African Health Products Regulatory Authority (SAHPRA) is concerned about the proliferation of falsified, compounded and substandard Glucagon-like Peptide (GLP-1)-containing products being made available to the public via websites, social media platforms and other informal channels. These pose a health…
The post SAHPRA’s position on GLP1 and GIP-GLP1 products that are compounded, substandard and falsified appeared first on SAHPRA.
SAHPRA
